SPOTLIGHT: Organogenesis plans fast-paced expansion

Organogenesis CEO Geoff MacKay tells the Boston Globe about the reasons why the developer is staying and expanding at new facilities in Massachusetts. And he also discusses his "tight timeline" to expand production and gain new approvals over the next three to four years. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.